拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMRN 拜玛林制药

盘后交易 09-08 17:19:10 EDT

64.63

-1.90

-2.86%

盘后65.14

+0.51+0.79%

16:10 EDT

最高66.26	最低64.01	成交量145.72万
今开65.24	昨收66.53	日振幅3.38%
总市值124.91亿	流通市值124.16亿	总股本1.93亿
成交额9,473万	换手率0.76%	流通股本1.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMRN","market":"US","secType":"STK","nameCN":"拜玛林制药","latestPrice":64.63,"timestamp":1788897600000,"preClose":66.53,"halted":0,"volume":1457213,"hourTrading":{"tag":"盘后","latestPrice":65.14,"preClose":64.63,"latestTime":"16:10 EDT","volume":53179,"amount":3437009.82184,"timestamp":1788898204906,"change":0.51,"changeRate":0.007891,"amplitude":0.007891},"delay":0,"changeRate":-0.02855854501728552,"floatShares":192116189,"shares":193270028,"eps":0.378983,"marketStatus":"盘后交易","change":-1.9,"latestTime":"09-08 17:19:10 EDT","open":65.24,"high":66.26,"low":64.01,"amount":94726299,"amplitude":0.033819,"askPrice":65.76,"askSize":4,"bidPrice":64.64,"bidSize":5,"shortable":3,"etf":0,"ttmEps":0.378983,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1788912000000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":932702400000,"exchange":"NASDAQ","adjPreClose":66.53,"preHourTrading":{"tag":"盘前","latestPrice":64.994,"preClose":66.53,"latestTime":"09:29 EDT","volume":1412,"amount":91991.71528,"timestamp":1788874192097,"change":-1.536,"changeRate":-0.023087,"amplitude":0.032566},"postHourTrading":{"tag":"盘后","latestPrice":65.14,"preClose":64.63,"latestTime":"16:10 EDT","volume":53179,"amount":3437009.82184,"timestamp":1788898204906,"change":0.51,"changeRate":0.007891,"amplitude":0.007891},"volumeRatio":0.701913,"impliedVol":0.4407,"impliedVolPercentile":0.6972},"requestUrl":"/m/hq/s/BMRN","defaultTab":"news","newsList":[{"id":"1183398041","title":"美股盘前｜美国打击伊朗，美股三大期指小幅走弱；能源股盘前走高，哈里伯顿、雪佛龙涨超2%；游戏驿站盘前涨3%，太平洋煤气电力暴跌17%","url":"https://stock-news.laohu8.com/highlight/detail?id=1183398041","media":"老虎资讯综合","labels":["AIColumn"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183398041?lang=zh_cn&edition=full","pubTime":"2026-08-31 20:21","pubTimestamp":1788178865,"startTime":"0","endTime":"0","summary":"热门股异动：受“英特尔将代工SK海力士新一代HBM基础芯片”消息提振，英特尔盘前微涨近0.2%，同时英伟达温和上扬，市场聚焦本周即将召开的AI生态大会；国际油价连涨激活能源板块，雪佛龙、西方石油、马拉松石油盘前普遍上涨约1%；博通在大行上调AI收入预期后小幅续涨，财报临近的情绪升温正在发酵。","market":"us","thumbnail":"https://static.tigerbbs.com/9fa7c522340c9f1e78e78f0c1543440e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9fa7c522340c9f1e78e78f0c1543440e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"AIColumn","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DE","NQmain","AON","PCG","ESmain","YMmain","BMRN","HAL"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1163200822","title":"异动解读｜拜玛林制药盘前上涨5.08%，与Ascendis达成全球专利和解获最高20%销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=1163200822","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163200822?lang=zh_cn&edition=full","pubTime":"2026-08-31 19:10","pubTimestamp":1788174635,"startTime":"0","endTime":"0","summary":"8月31日，拜玛林制药盘前上涨5.08%，报68.82美元/股，成交额30.09万美元。消息面上，拜玛林制药宣布与Ascendis Pharma就罕见病药物Yuviwel达成具有约束力的全球专利和解协议。根据协议，Ascendis将就Yuviwel在美国市场的净销售额向拜玛林支付20%的特许权使用费，在欧盟、巴西及韩国市场的销售额支付18%，支付期限延续至2030年5月。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"拜玛林盘前上涨，与Ascendis和解获最高20%分成","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077819","title":"拜玛林制药（BMRN）与Ascendis就罕见病药物达成全球专利和解 获最高20%销售分成","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077819","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663077819?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:47","pubTimestamp":1788173270,"startTime":"0","endTime":"0","summary":"作为回报，拜玛林制药将向Ascendis授予针对Yuviwel所有现行及潜在适应症以及联合用药方案的专利许可，并撤回在美国国际贸易委员会发起的337调查以及在德国、丹麦、巴西、韩国和美国加州北区法院挂牌的诉讼。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDEzNTY0MzU1NjUy.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305490","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4139","IE00B7SZLL34.SGD","AZNH","IE0002270589.USD","IE00B19Z3B42.SGD","BK4566","BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152003599","title":"拜玛林制药盘前股价攀升5.6%，宣布与Ascendis Pharma达成全球和解","url":"https://stock-news.laohu8.com/highlight/detail?id=1152003599","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152003599?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:38","pubTimestamp":1788165495,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）的股价在盘前交易时段上扬5.6%。这一涨幅源于公司宣布已与Ascendis Pharma达成全球和解协议。市场对这一消息反应积极，推动股价走强。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B19Z3581.USD","LU0109394709.USD","LU0320765992.SGD","BK4585","IE00B7SZLL34.SGD","BMRN","ASND","LU0889565916.HKD","MEDI","IE0002270589.USD","BK4566","IE00B19Z3B42.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172567405","title":"拜玛林制药将撤销ITC调查；包括多国诉讼在内的所有知识产权索赔已解决","url":"https://stock-news.laohu8.com/highlight/detail?id=1172567405","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172567405?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:02","pubTimestamp":1788156130,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，将撤销美国国际贸易委员会（ITC）的调查。该公司表示，所有知识产权相关主张均已得到解决，其中涵盖了在多个国家进行的诉讼。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASND","LU0109394709.USD","LU0889565916.HKD","LU0320765992.SGD","MEDI","BK4139","IE00B19Z3581.USD","IE00B19Z3B42.SGD","BK4566","BK4585","IE0002270589.USD","BMRN","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113752651","title":"拜玛林制药达成和解协议：获Yuviwel全适应症相关专利许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1113752651","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113752651?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:01","pubTimestamp":1788156073,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，其和解方案中涵盖了一项关键条款——即针对Yuviwel药物所有适应症所涉及的专利，拜玛林将获得相应许可。这项和解内容包括，拜玛林将就其与Yuviwel相关的专利组合授予许可，适用范围覆盖全部适应症领域。根据协议内容，此次许可范围之广，触及Yuviwel所有可能的应用场景。此次公布的协议是整体和解方案的一部分，其核心在于为拜玛林提供清晰的专利使用权限。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","BMRN","IE00B19Z3B42.SGD","BK4139","BK4566","IE00B19Z3581.USD","IE0002270589.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159264208","title":"拜玛林制药达成授权协议：Ascendis就Yuviwel美国销售支付20%特许权使用费，欧盟、巴西及韩国为18%，持续至2030年5月","url":"https://stock-news.laohu8.com/highlight/detail?id=1159264208","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1159264208?lang=zh_cn&edition=full","pubTime":"2026-08-31 14:01","pubTimestamp":1788156072,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布了一项重要授权安排。根据协议条款，Ascendis公司将针对其药物Yuviwel在美国市场的销售额，向拜玛林支付20%的特许权使用费。而在欧盟、巴西及韩国等地区，这一比例则为18%。该支付义务将延续至2030年5月。对Ascendis而言，这一安排意味着其旗舰产品Yuviwel在全球主要市场的商业化进程中，需承担相应的授权成本。随着协议的正式生效，业界将密切关注Yuviwel在各大市场的实际销售表现，以及这一财务安排对两家公司未来业绩的潜在影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","BK4139","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191918291","title":"拜玛林制药收购Alesta Therapeutics，斩获低磷酸酯酶症首款潜在口服疗法Ale1，重磅临床项目并入管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1191918291","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191918291?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:31","pubTimestamp":1787056284,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，将收购Alesta Therapeutics公司，以此获得其核心资产Ale1——一款有望成为低磷酸酯酶症首个口服治疗方案的在研药物。此项交易为拜玛林的研发管线增添了一个至关重要的临床项目。此次收购，标志着拜玛林在拓展其产品组合方面迈出了坚实一步。通过整合Alesta Therapeutics的研发实力与拜玛林的商业化经验，双方有望加速Ale1的临床开发进程，早日惠及全球患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BMRN","IE00B7SZLL34.SGD","BK4139","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180971002","title":"拜玛林制药与N-Lorem达成全球独家授权，共同开发Renu综合征反义寡核苷酸药物","url":"https://stock-news.laohu8.com/highlight/detail?id=1180971002","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1180971002?lang=zh_cn&edition=full","pubTime":"2026-07-27 21:14","pubTimestamp":1785158066,"startTime":"0","endTime":"0","summary":"拜玛林制药与N-Lorem联合宣布，双方已签署一项全球独家许可协议，旨在推动针对Renu综合征的反义寡核苷酸（ASO）疗法研发。此举标志着两家机构在罕见病治疗领域迈出了关键一步，为患者带来潜在的新希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B7SZLL34.SGD","BMRN","BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115162702","title":"美国食品药品监督管理局受理拜玛林制药关于Voxzogo® (vosoritide)用于软骨发育不全儿童完全批准的补充新药申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1115162702","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115162702?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:18","pubTimestamp":1783948727,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已正式受理拜玛林制药提交的补充新药申请，该申请旨在为药物Voxzogo® (vosoritide)在治疗儿童软骨发育不全症方面获得完全批准。此举标志着该药物在监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4566","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE0002270589.USD","BMRN","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127221100","title":"拜玛林制药III期研究显示第52周时年化生长速度增加2.33厘米/年","url":"https://stock-news.laohu8.com/highlight/detail?id=1127221100","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127221100?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:21","pubTimestamp":1779308506,"startTime":"0","endTime":"0","summary":"拜玛林制药公司公布的一项III期临床试验数据显示，在治疗第52周时，患者的年化生长速度实现了显著提升，增幅达到2.33厘米/年。这一积极结果凸显了其在研疗法在促进生长方面的潜力，为后续的研发与审批进程提供了关键支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BMRN","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","BK4566","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151320774","title":"拜玛林制药宣布Voxzogo® (Vosoritide) 在软骨发育不全儿童中取得积极三期关键研究结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1151320774","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151320774?lang=zh_cn&edition=full","pubTime":"2026-05-21 04:21","pubTimestamp":1779308486,"startTime":"0","endTime":"0","summary":"拜玛林制药公布了其药物Voxzogo® (Vosoritide) 针对软骨发育不全儿童患者的三期关键性研究的积极成果。该研究达到了主要终点，显示治疗取得了显著效果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZLL34.SGD","BK4139","BK4566","IE0002270589.USD","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101027296","title":"基因疗法后期试验结果喜忧参半，拜玛林制药股价应声下跌1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1101027296","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101027296?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:47","pubTimestamp":1779112039,"startTime":"0","endTime":"0","summary":"拜玛林制药（Biomarin Pharmaceutical）一项针对遗传性疾病的疗法在后期研究中呈现出复杂的数据结果，市场对此反应审慎，公司股价应声下跌约1%。\n这项关键临床试验的结果未能提供明确一致的成功信号，导致投资者信心受挫。尽管疗法在某些评估指标上显示出积极潜力，但整体数据的混合性引发了对其最终疗效与商业化前景的重新评估。\n股价的即时波动反映了市场对生物科技公司研发管线不确定性的典型定价行为。在高度依赖单一或少数重磅产品驱动的行业里，临床数据的任何模糊性都可能迅速转化为资本市场的压力。此次下跌凸显了在创新疗法开发过程中，从科学验证到市场接纳所面临的严峻挑战。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4139","BK4566","IE0002270589.USD","IE00B19Z3581.USD","BMRN","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1184770893","title":"拜玛林制药ENERGY 3研究：放射学整体印象变化评分未现改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1184770893","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184770893?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:11","pubTimestamp":1779109895,"startTime":"0","endTime":"0","summary":"拜玛林制药公司近日公布的ENERGY 3研究结果显示，其评估指标——放射学整体印象变化评分——并未出现具有统计学意义的改善。这一核心数据未能达到研究预设的终点，引发了市场对该疗法潜在疗效的进一步审视。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","BK4139","IE00B19Z3581.USD","IE0002270589.USD","BMRN","IE00B7SZLL34.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198173165","title":"拜玛林制药：佝偻病严重程度评分与生长Z评分等次要终点未见积极趋势","url":"https://stock-news.laohu8.com/highlight/detail?id=1198173165","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198173165?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:07","pubTimestamp":1779109622,"startTime":"0","endTime":"0","summary":"拜玛林制药公司近日公布的数据显示，其研究中的关键次要终点，包括佝偻病严重程度评分与生长Z评分，均未观察到积极的改善趋势。\n这一结果引发了市场对其相关疗法前景的进一步审视。分析人士指出，次要终点的表现对于全面评估治疗效果至关重要，当前数据的缺乏亮点可能意味着需要更深入的分析或更长的观察周期。\n公司方面尚未就这些具体数据发表进一步评论。投资者正密切关注后续可能披露的更多细节，以评估其对整体研发管线价值的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B7SZLL34.SGD","IE0002270589.USD","BK4139","IE00B19Z3B42.SGD","IE00B19Z3581.USD","BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186367310","title":"拜玛林制药Bmn 401在ENERGY 3研究中显示血浆无机焦磷酸盐显著增加","url":"https://stock-news.laohu8.com/highlight/detail?id=1186367310","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186367310?lang=zh_cn&edition=full","pubTime":"2026-05-18 21:06","pubTimestamp":1779109609,"startTime":"0","endTime":"0","summary":"拜玛林制药公司宣布，其候选药物Bmn 401在ENERGY 3研究中的数据显示，能够显著提升患者血浆中的无机焦磷酸盐水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3581.USD","BK4139","IE00B7SZLL34.SGD","IE0002270589.USD","IE00B19Z3B42.SGD","BK4566","BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192554879","title":"拜玛林制药在儿科内分泌学会2026年会公布Voxzogo长期治疗对软骨发育不全患儿臂展、骨骼健康及生长影响的新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1192554879","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192554879?lang=zh_cn&edition=full","pubTime":"2026-05-03 03:30","pubTimestamp":1777750216,"startTime":"0","endTime":"0","summary":"拜玛林制药于儿科内分泌学会2026年度会议上，公布了关于Voxzogo长期治疗对软骨发育不全患儿臂展、骨骼健康及生长影响的最新研究数据。该研究深入探讨了Vosoritide持续用药对患儿多项生理指标产生的积极效果。\n最新分析结果显示，长期接受Voxzogo治疗的患儿在臂展发育、骨骼健康指标及整体生长参数方面均表现出显著改善。这些发现为Vosoritide在改善软骨发育不全患儿生活质量方面的长期疗效提供了重要临床证据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","BK4566","IE00B7SZLL34.SGD","BK4139","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157902853","title":"拜玛林制药：因两项研究者发起试验中发生多起股骨头骨骺滑脱事件而决定终止研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1157902853","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157902853?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664512,"startTime":"0","endTime":"0","summary":"拜玛林制药宣布，由于两项正在进行的研究者发起试验中出现了数例股骨头骨骺滑脱事件，公司已决定终止这些研究项目。该决定基于对患者安全的审慎评估，旨在优先保障临床试验参与者的福祉。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","IE00B19Z3B42.SGD","IE0002270589.USD","IE00B7SZLL34.SGD","BK4139","BMRN","IE00B19Z3581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513372995","title":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513372995","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513372995?lang=zh_cn&edition=full","pubTime":"2025-02-24 21:17","pubTimestamp":1740403022,"startTime":"0","endTime":"0","summary":"奥本海默：上调Biomarin Pharmaceutical(BMRN.US)评级，由Perform调整至优于大市评级, 目标价98.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/24211748352370.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111972741","title":"异动解读 | 财报远超预期,拜玛林制药盘前大涨10.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111972741","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111972741?lang=zh_cn&edition=full","pubTime":"2025-02-20 18:18","pubTimestamp":1740046705,"startTime":"0","endTime":"0","summary":"2025年第四季度财报出炉,拜玛林制药公司大幅超过了市场预期,这一利好消息推动公司股价在今日盘前大涨10.52%。\n\n拜玛林制药此前公布的2025年第四季度每股收益为0.92美元,远高于市场预期的0.53美元;季度销售额也创下7.4731亿美元的新高。此番罕见的业绩喜讯,令投资者看好公司进一步发展前景。\n\n作为领先的罕见疾病专业制药企业,拜玛林制药的出色表现得益于其管线和产品创新所带来的增长。投资界普遍认为,在需求不断增长的罕见疾病领域,公司将凭借领先优势开发新药并扩大收入来源,高速增长将延续。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BMRN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bmrn.com","stockEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.1105},{"period":"3month","weight":0.1719},{"period":"6month","weight":0.0885},{"period":"1year","weight":0.1723},{"period":"ytd","weight":0.1195}],"compareEarnings":[{"period":"1week","weight":0.0011},{"period":"1month","weight":0.0005},{"period":"3month","weight":0.0443},{"period":"6month","weight":0.1455},{"period":"1year","weight":0.1865},{"period":"ytd","weight":0.1294}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biomarin Pharmaceutical Inc.于1996年10月在特拉华州注册成立，并于1997年3月21日开始运营。该公司是一家全球性生物技术公司，致力于将基因发现的前景转化为对每位患者的生活产生深远影响的药物。T. BioMarin为代表重大未满足医疗需求的疾病和病症选择候选产品，这些疾病和病症具有很好的生物学理解，并提供了率先上市或提供优于现有产品的机会。该公司的产品组合由四个已获批准的产品和多个研究候选产品组成。","yearOnYearQuotes":[{"month":1,"riseRate":0.62963,"avgChangeRate":0.046047},{"month":2,"riseRate":0.481481,"avgChangeRate":0.016135},{"month":3,"riseRate":0.444444,"avgChangeRate":0.001463},{"month":4,"riseRate":0.481481,"avgChangeRate":-0.01987},{"month":5,"riseRate":0.518519,"avgChangeRate":0.008278},{"month":6,"riseRate":0.592593,"avgChangeRate":0.016302},{"month":7,"riseRate":0.666667,"avgChangeRate":0.039874},{"month":8,"riseRate":0.571429,"avgChangeRate":0.005021},{"month":9,"riseRate":0.464286,"avgChangeRate":-0.011601},{"month":10,"riseRate":0.407407,"avgChangeRate":-0.026394},{"month":11,"riseRate":0.814815,"avgChangeRate":0.061245},{"month":12,"riseRate":0.62963,"avgChangeRate":0.034544}],"exchange":"NASDAQ","name":"拜玛林制药","nameEN":"Biomarin Pharmaceutical"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拜玛林制药,BMRN,拜玛林制药股票,拜玛林制药股票老虎,拜玛林制药股票老虎国际,拜玛林制药行情,拜玛林制药股票行情,拜玛林制药股价,拜玛林制药股市,拜玛林制药股票价格,拜玛林制药股票交易,拜玛林制药股票购买,拜玛林制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拜玛林制药(BMRN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拜玛林制药(BMRN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}